M&A

Northern Irish biostatistics and data science company, Exploristics, has announced that it has been acquired by MMS.

The acquisition will allow MMS to leverage Exploristics’ KerusCloud software, increasing its expertise in ‘advanced clinical trial design, innovative statistics and data science’, according to the company’s press release. The KerusCloud software is a cloud-based statistical modelling system that can also act as a simulation platform.

The US-based contract research organisation (CRO) claims that the acquisition will also aid in improving drug development in orphan, rare and special disease spaces by allowing for enhanced research and real-time pivots.

Dr Uma Sharma, CEO at MMS, stated: “We are proud to bring the Exploristics team into the #OneMMS family. When exploring acquisition opportunities to enhance our strategic capabilities as a leading data CRO, we sought organisations that would complement our existing regulatory approach, and build a powerful combination of regulatory and statistical design expertise, combined with market-leading study simulation software. We found that in Exploristics, along with a like-minded culture.”

Aiden Flynn, founder and CEO of Exploristics, added: “Joining MMS represents an exciting new chapter for Exploristics. Our ethos has always centred on openness, honesty, professionalism, flexibility and creativity – qualities I’ve experienced at MMS since day one of our discussions. I am confident our employees, partners and clients will benefit from this partnership as we amplify our impact and expand our global reach.”